CARM Carisma Therapeutics Inc: רווח למניה בשנים עשר החודשים האחרונים

The TTM net income per share reflects capital dynamics, where -1.18 indicates the current level for Carisma Therapeutics (CARM). Geopolitical tensions and sanctions complicate raw material logistics and international trials. Simultaneously, strategic alliances with tech giants are accelerating the development of solid tumor therapies. However, substantial early-stage research expenditures and the risk of trial failure are putting pressure on the balance sheet.
פילוחים אנליטיים ודוחות נתונים של חברת Carisma Tx (CARM)

EPS TTM determines investment reliability by reflecting the actual return per share. This metric aggregates net income over the year, neutralizing the impact of short-term fluctuations and capital dilution. By analyzing the 12-month trend of net income per share, an investor assesses the efficiency of resource management. For Carisma Therapeutics (CARM), this trend is supported by a stable R&D core. Retaining macrophage experts through stock options guarantees technological progress without personnel losses.